Clinical Trial Update: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update describes a Quad CAR T cell therapy targeting B7-H3, EGFR806, HER2, and IL13-Zetakine for pediatric diffuse intrinsic pontine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Diffuse Midline Glioma

Drugs mentioned

• B7-H3 CAR T (B7-H3 targeted CAR T)
• EGFR806 CAR T (EGFR806-targeted CAR T)
• HER2 CAR T (HER2-targeted CAR T)
• IL13-Zetakine CAR T (IL13 zetakine CAR T)
• Quad CAR T Cell Therapy (B7-H3, EGFR806, HER2, IL13-Zetakine)

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING